메뉴 건너뛰기




Volumn 43, Issue 2, 2016, Pages 240-251

Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

EID: 84954189862     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13461     Document Type: Article
Times cited : (201)

References (20)
  • 1
    • 84891669630 scopus 로고    scopus 로고
    • New and future drug development for gastroesophageal reflux disease
    • Maradey-Romero C, Fass R,. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014; 20: 6-16.
    • (2014) J Neurogastroenterol Motil , vol.20 , pp. 6-16
    • Maradey-Romero, C.1    Fass, R.2
  • 2
    • 84868017013 scopus 로고    scopus 로고
    • Burden of gastrointestinal disease in the United States: 2012 update
    • Peery AF, Dellon ES, Lund J, et al,. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.
    • (2012) Gastroenterology , vol.143 , pp. 1179-1187
    • Peery, A.F.1    Dellon, E.S.2    Lund, J.3
  • 3
    • 0030931230 scopus 로고    scopus 로고
    • Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
    • Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd,. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
    • (1997) Gastroenterology , vol.112 , pp. 1448-1456
    • Locke, G.R.1    Talley, N.J.2    Fett, S.L.3    Zinsmeister, A.R.4    Melton, L.J.5
  • 4
    • 0030962574 scopus 로고    scopus 로고
    • Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
    • Chiba N, De Gara CJ, Wilkinson JM, Hunt RH,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
    • (1997) Gastroenterology , vol.112 , pp. 1798-1810
    • Chiba, N.1    De Gara, C.J.2    Wilkinson, J.M.3    Hunt, R.H.4
  • 5
    • 17644416461 scopus 로고    scopus 로고
    • Epidemiology of gastro-oesophageal reflux disease: A systematic review
    • Dent J, El-Serag HB, Wallander MA, Johansson S,. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
    • (2005) Gut , vol.54 , pp. 710-717
    • Dent, J.1    El-Serag, H.B.2    Wallander, M.A.3    Johansson, S.4
  • 6
    • 84899976398 scopus 로고    scopus 로고
    • Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review
    • El-Serag HB, Sweet S, Winchester CC, Dent J,. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
    • (2014) Gut , vol.63 , pp. 871-880
    • El-Serag, H.B.1    Sweet, S.2    Winchester, C.C.3    Dent, J.4
  • 8
    • 0141539363 scopus 로고    scopus 로고
    • Short-term treatment of gastroesophageal reflux disease
    • van Pinxteren B, Numans ME, Lau J, et al,. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755-63.
    • (2003) J Gen Intern Med , vol.18 , pp. 755-763
    • Van Pinxteren, B.1    Numans, M.E.2    Lau, J.3
  • 9
    • 84858699762 scopus 로고    scopus 로고
    • Alternative therapeutic approaches to chronic proton pump inhibitor treatment
    • Fass R,. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2012; 10: 338-45.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 338-345
    • Fass, R.1
  • 10
    • 80054787732 scopus 로고    scopus 로고
    • Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438)
    • Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
    • (2011) J Pharmacol Exp Ther , vol.339 , pp. 412-420
    • Shin, J.M.1    Inatomi, N.2    Munson, K.3
  • 11
    • 77957228369 scopus 로고    scopus 로고
    • 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
    • Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
    • (2010) J Pharmacol Exp Ther , vol.335 , pp. 231-238
    • Hori, Y.1    Imanishi, A.2    Matsukawa, J.3
  • 12
    • 79953716223 scopus 로고    scopus 로고
    • A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
    • Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
    • (2011) Biochem Pharmacol , vol.81 , pp. 1145-1151
    • Matsukawa, J.1    Hori, Y.2    Nishida, H.3
  • 13
    • 79956193494 scopus 로고    scopus 로고
    • A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals
    • Hori Y, Matsukawa J, Takeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
    • (2011) J Pharmacol Exp Ther , vol.337 , pp. 797-804
    • Hori, Y.1    Matsukawa, J.2    Takeuchi, T.3
  • 14
    • 84989307721 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects
    • Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94. doi: 10.1038/ctg.2015.18
    • (2015) Clin Transl Gastroenterol , vol.6 , pp. e94
    • Sakurai, Y.1    Nishimura, A.2    Kennedy, G.3
  • 15
    • 84964207179 scopus 로고    scopus 로고
    • Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
    • Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
    • (2015) Aliment Pharmacol Ther , vol.41 , pp. 636-648
    • Jenkins, H.1    Sakurai, Y.2    Nishimura, A.3
  • 16
    • 84939568162 scopus 로고    scopus 로고
    • Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. Lansoprazole for the treatment of erosive oesophagitis
    • Ashida K, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42: 685-95.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 685-695
    • Ashida, K.1    Sakurai, Y.2    Nishimura, A.3
  • 17
    • 36549032595 scopus 로고    scopus 로고
    • A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
    • Kahrilas PJ, Dent J, Lauritsen K, et al,. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 1385-1391
    • Kahrilas, P.J.1    Dent, J.2    Lauritsen, K.3
  • 18
    • 0025633361 scopus 로고
    • Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk
    • Farrington CP, Manning G,. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54.
    • (1990) Stat Med , vol.9 , pp. 1447-1454
    • Farrington, C.P.1    Manning, G.2
  • 19
    • 28144433010 scopus 로고    scopus 로고
    • Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases
    • Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
    • (2005) Pharmacol Ther , vol.108 , pp. 294-307
    • Andersson, K.1    Carlsson, E.2
  • 20
    • 84882756075 scopus 로고    scopus 로고
    • Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis - A phase III, multicenter, randomized, double-blind trial
    • Kinoshita Y, Miwa H, Kasugai K,. Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis-a phase III, multicenter, randomized, double-blind trial. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 1428-38.
    • (2013) Nihon Shokakibyo Gakkai Zasshi , vol.110 , pp. 1428-1438
    • Kinoshita, Y.1    Miwa, H.2    Kasugai, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.